Literature DB >> 19055685

CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.

C Klemann1, J Schade, R Pabst, S Leitner, J Stiller, S von Hörsten, M Stephan.   

Abstract

As CD26 (dipeptidyl peptidase 4/DPP4) rapidly truncates incretins N-terminally, including glucagon-like peptide-1, DPP4-inhibitors have been developed for treatment of diabetes type 2. To some extent this is surprising, as CD26/DPP4 is also deeply involved in immune regulation. Long-term pharmacological studies are hampered by off-target inhibition of DPP4-homologues. Therefore, we studied the effects of genetic CD26/DPP4-deficiency by investigating blood, spleen and thymus leucocyte subpopulations of wild-type and CD26-deficient F344-rats at different ages. In young animals at 1 and 3 months of age, there were no differences in leucocyte subsets, while in older animals the T cell composition was changed significantly. From the age of 6 months onwards, reduced numbers of recent thymic emigrants and memory T cells, and consequently an increased amount of naive T cells were observed in CD26-deficient rats. In addition, the architecture of the thymus was altered, as observed by a reduced density of lymphocytes in the medulla. Furthermore, the number of proliferating cells in the thymus was decreased in CD26-deficient rats at a higher age. Moreover, CD26-deficiency resulted in markedly reduced numbers of B cells in later life. Additionally, an age- but not CD26-dependent increase of regulatory T cells and a decrease of natural killer cell numbers were detected in the blood and spleen. Our findings indicate an important role of CD26 in maintaining lymphocyte composition, memory T cell generation and thymic emigration patterns during immunosenescence, with possible implications for using DPP4-inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19055685      PMCID: PMC2675268          DOI: 10.1111/j.1365-2249.2008.03839.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Finding new treatments for diabetes--how many, how fast... how good?

Authors:  David M Nathan
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

Review 2.  Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.

Authors:  Kei Ohnuma; Nam H Dang; Chikao Morimoto
Journal:  Trends Immunol       Date:  2008-05-02       Impact factor: 16.687

3.  Discovery of dipeptidyl-peptidase IV--a 40 year journey from bench to patient.

Authors:  V Koivisto
Journal:  Diabetologia       Date:  2008-04-03       Impact factor: 10.122

Review 4.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

Review 5.  Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

Authors:  Carolyn F Deacon; Jens J Holst
Journal:  Int J Biochem Cell Biol       Date:  2005-10-03       Impact factor: 5.085

6.  Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo.

Authors:  Milica Vukmanovic-Stejic; Yan Zhang; Joanne E Cook; Jean M Fletcher; Arthur McQuaid; Joanne E Masters; Malcolm H A Rustin; Leonie S Taams; Peter C L Beverley; Derek C Macallan; Arne N Akbar
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

7.  Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma.

Authors:  Thomas Skripuletz; Andreas Schmiedl; Jutta Schade; Sammy Bedoui; Thomas Glaab; Reinhard Pabst; Stephan von Hörsten; Michael Stephan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-03-09       Impact factor: 5.464

Review 8.  T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Authors:  Kei Ohnuma; Hiroshi Inoue; Masahiko Uchiyama; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

9.  Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.

Authors:  Kei Ohnuma; Masahiko Uchiyama; Tadanori Yamochi; Kunika Nishibashi; Osamu Hosono; Nozomu Takahashi; Shinichiro Kina; Hirotoshi Tanaka; Xin Lin; Nam H Dang; Chikao Morimoto
Journal:  J Biol Chem       Date:  2007-02-06       Impact factor: 5.157

10.  Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease.

Authors:  Silke Nuber; Elisabeth Petrasch-Parwez; Beate Winner; Jürgen Winkler; Stephan von Hörsten; Thorsten Schmidt; Jana Boy; Melanie Kuhn; Huu P Nguyen; Peter Teismann; Jörg B Schulz; Manuela Neumann; Bernd J Pichler; Gerald Reischl; Carsten Holzmann; Ina Schmitt; Antje Bornemann; Wilfried Kuhn; Frank Zimmermann; Antonio Servadio; Olaf Riess
Journal:  J Neurosci       Date:  2008-03-05       Impact factor: 6.167

View more
  12 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

Authors:  Elena Matteucci; Massimo Ghimenti; Serena Di Beo; Ottavio Giampietro
Journal:  J Clin Immunol       Date:  2011-09-02       Impact factor: 8.317

Review 3.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

4.  DPP4 deficiency preserved cardiac function in abdominal aortic banding rats.

Authors:  Hui-Chun Ku; Ming-Jai Su
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

Review 5.  Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.

Authors:  Jaquellyne Gurgel Penaforte-Saboia; Carlos Eduardo Barra Couri; Natasha Vasconcelos Albuquerque; Vanessa Lauanna Lima Silva; Natália Bitar da Cunha Olegario; Virgínia Oliveira Fernandes; Renan Magalhães Montenegro Junior
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-10       Impact factor: 3.168

6.  Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.

Authors:  Núria Alonso; María Teresa Julián; Jorge Carrascal; Roger Colobran; Irma Pujol-Autonell; Silvia Rodriguez-Fernández; Aina Teniente; Marco Antonio Fernández; Antoni Miñarro; María Carmen Ruiz de Villa; Marta Vives-Pi; Manel Puig-Domingo
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

7.  Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time.

Authors:  Michael Stephan; Hendrik Suhling; Jutta Schade; Mareike Wittlake; Tihana Tasic; Christian Klemann; Reinhard Pabst; Marie-Charlot Jurawitz; Kerstin A Raber; Heinz G Hoymann; Armin Braun; Thomas Glaab; Torsten Hoffmann; Andreas Schmiedl; Stephan von Hörsten
Journal:  Physiol Rep       Date:  2013-10-02

8.  Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants.

Authors:  Carlos Alberto Moreira-Filho; Silvia Yumi Bando; Fernanda Bernardi Bertonha; Filipi Nascimento Silva; Luciano da Fontoura Costa; Leandro Rodrigues Ferreira; Glaucio Furlanetto; Paulo Chacur; Maria Claudia Nogueira Zerbini; Magda Carneiro-Sampaio
Journal:  Oncotarget       Date:  2016-02-16

Review 9.  Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.

Authors:  Shiying Shao; QinQin Xu; Xuefeng Yu; Ruping Pan; Yong Chen
Journal:  Pharmacol Ther       Date:  2020-02-14       Impact factor: 12.310

10.  Lung development and immune status under chronic LPS exposure in rat pups with and without CD26/DPP4 deficiency.

Authors:  Stephan von Hörsten; Michael Stephan; Andreas Schmiedl; Inga Wagener; Meike Jungen
Journal:  Cell Tissue Res       Date:  2021-10-04       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.